<DOC>
	<DOCNO>NCT02656615</DOCNO>
	<brief_summary>To assess activity abiraterone-re-challenge patient advanced prostate cancer prior response abiraterone .</brief_summary>
	<brief_title>Abiraterone-Rechallenge Study CRPC Patients</brief_title>
	<detailed_description>To assess activity abiraterone-re-challenge patient advanced prostate cancer prior response abiraterone . CRPC patient prior response abiraterone ( confirm PSA Response ) progression re-challenged abiraterone . Patients may receive treatment docetaxel , enzalutamide radium-223 .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>1 . Written prostate cancer . 2 . Adult patient histological cytological diagnosis adenocarcinoma prostate . 3 . Men castrationresistant metastatic decline maintain least 3 week per PCWG2 criterion ) . 4 . Confirmed biochemical response prior abiraterone acetate ( ≥50 % PSA Informed Consent ( include consent biomarker study include fresh tumour biopsy ) 5 . Progressive disease accord PCWG2 criterion prior therapy standard dose abiraterone acetate ( confirmed increase PSA ≥25 % nadir ) softtissue bone progression . Patients stop abiraterone acetate reason progression eligible . 6 . Documented progression disease criterion list : PSA Soft tissue Bone scan per PCWG2 criterion 7 . Patients may receive treatment docetaxel , enzalutamide radium223 8 . PSA ≥10ug/l 9 . ECOG performance status 0 2 10 . At least 3 month ( 90 day ) since stop prior abiraterone acetate . 1 . Major surgery within 28 day week prior start treatment 2 . Prior treatment cabazitaxel CYP17 inhibitor TAK700/orteronel 3 . Any concurrent treatment prior treatment investigational drug within 28 day prior start treatment . 4 . Known brain leptomeningeal disease 5 . Concurrent use steroid prednisone &gt; 10mg/d 6 . Inadequate bone marrow organ function evidence : Platelet count &lt; 75 x 10 G/L ASAT and/or ALAT ≥ 2.5 x ULN Total bilirubin ≥ 1.5 x ULN ( ≥ 2.0 x ULN patient Gilbert 's disease ) Hypokalaemia despite adequate supplementation Creatinine Clearance &lt; 30ml/min 7 . Uncontrolled hypertension cardiac failure LVEF &lt; 50 % creatinine clearance calculate use formula CockcroftGault appendix 4 protocol</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>